A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: An eastern cooperative oncology group study (E1404)

Daniel R. Greenwald, Hailun Li, Selina M. Luger, Ronald S. Go, David King, Taral Patel, Randy D. Gascoyne, Jill Kolesar, Brad S. Kahl, Sandra Horning

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Patients with diffuse large B cell lymphoma (DLBCL) who are not candidates for or recur after autologous stem cell transplant have a poor overall prognosis. We conducted a phase II study of sorafenib (formerly BAY 43-9006) in the treatment of relapsed DLBCL. Fourteen patients were enrolled and assessed for response. Median number of cycles administered was 3 (range, 1-12). Common grade 3 toxicities included fatigue (29%), rash/desquamation (21%) and diarrhea (14%). One complete response (CR) was observed (the 14th patient enrolled). Response rate was 7% (90% CI, 0.4 - 30%). Duration of response was 6 months. Median progression-free survival (PFS) was 2 months (90% CI, 1 - 5 months). Median overall survival (OS) was 9 months (90% CI, 5 - 16 months). Although sorafenib has demonstrated activity in solid malignancies it demonstrated low single agent activity in treatment of DLBCL.

Original languageEnglish
Article number46
JournalJournal of Hematology and Oncology
Volume6
Issue number1
DOIs
StatePublished - 2013

Bibliographical note

Funding Information:
We would like to thank Dr. Ranjana Advani for her help in study implementation and review of the manuscript. This investigation was supported by Grant CA-23318, awarded by the National Cancer Institute, DHHS. This study was conducted by the Eastern Cooperative Oncology Group (Robert L. Comis, M.D., Chair) and supported in part by Public Health Service Grants CA21115, CA23318, CA66636, CA15488, CA21076 and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

Funding

We would like to thank Dr. Ranjana Advani for her help in study implementation and review of the manuscript. This investigation was supported by Grant CA-23318, awarded by the National Cancer Institute, DHHS. This study was conducted by the Eastern Cooperative Oncology Group (Robert L. Comis, M.D., Chair) and supported in part by Public Health Service Grants CA21115, CA23318, CA66636, CA15488, CA21076 and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

FundersFunder number
National Institutes of Health (NIH)
U.S. Department of Health and Human Services
National Childhood Cancer Registry – National Cancer InstituteU10CA066636
U.S. Public Health ServiceCA15488, CA21076, CA-23318, CA21115

    Keywords

    • Diffuse large B cell lymphoma
    • MAP kinase signaling
    • NHL
    • Sorafenib

    ASJC Scopus subject areas

    • Molecular Biology
    • Hematology
    • Oncology
    • Cancer Research

    Fingerprint

    Dive into the research topics of 'A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: An eastern cooperative oncology group study (E1404)'. Together they form a unique fingerprint.

    Cite this